"Pingene" Introduce
The Pingene Platform
——— Product advantages
Advantages
Set cancer detection kit research and development, production, sales as oneThe company has successfully developed a series of in vitro detection products of "cancer liquid gene detection" with completely independent intellectual property rights, and applied the unique technology of adding molecular barcode to the determination of circulating tumor DNA (ctDNA), so as to dynamically track the real-time changes of cancer occurrence and progress. Compared with similar products at home and abroad, the company has the advantages of "more accurate, more sensitive and more reliable" The main indexes have exceeded or reached the international advanced level. At present, we are preparing to apply for the national class III medical device registration certificate.
——— product value
Value
"Precision treatment" is the main development trend of medicine in the future. The premise of precision treatment is "accurate diagnosis". Our products belong to the subdivision field of "accurate diagnosis" of cancer.
In 2015 (Note: cancer statistics are generally released three years behind), 4.292 million new cancer patients and 2.814 million deaths were added in the country; The number of cancer has increased by 3.9% annually in the past 10 years, and it is estimated that by 2019, the number of new cancer patients will reach 5million new cancer patients in China.
In 2015, liquid biopsy was ranked the top ten technological breakthroughs in the year by MIT; In june2017, the world economic forum and the expert committee of science American magazine jointly elected the top ten emerging technologies in the world in 2017, among which the non-invasive diagnosis technology of tumor was selected and won the top.
Piperjaffray estimated that the optimistic, neutral and pessimistic estimates of the market space for tumor liquid biopsy were about 150billion yuan, 112.5 billion yuan and 75billion yuan respectively. Based on the above analysis, the cancer liquid biopsy market predicted by 2025 will be around 90billion yuan, between the pessimistic and neutral predictions of piperjaffray. According to incomplete statistics, the market scale of tumor liquid biopsy in 2019 is about 13billion yuan.
——— Core technologies
Technologies
Based on two patents (Chinese invention patents: 201810193450.5 and 201810193448.8) independently developed by our company with full intellectual property rights, we use them for gene detection including cancer gene detection
This patent technology is different from the current technical route and detection method. We are quantitative determination of ctDNA or ccfdna in body fluid. In other words, we are detecting the absolute value of ctDNA or ccfdna in body fluid, rather than the ratio of ctDNA and ccfdna. This is the first detection method at home and abroad, with milestone significance!
